RxDoctor Payments DataLook up a doctor →

John Wulff, MD

Neurology · Muncie, INNPI 1477530913

Payments from drug & device makers

$141,576in general payments, 2019–2025

Across 440 payments — averaging $321.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$37K
  • AbbVie$29K
  • Acorda Therapeutics, Inc$28K
  • Biohaven Pharmaceutical Holding Company Ltd.$26K
  • Adamas Pharmaceuticals, Inc.$18K
  • MDD US Operations, LLC$660
  • plus $3K from 41 others

What the payments were for

  • Consulting fees$5000%
  • Speaking & faculty fees$129,13191%
  • Travel & lodging$5,3754%
  • Food & beverage$6,5705%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$141,576 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$34,674
Medicare patients
243
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
InbrijaLevodopa13$80,518
Nurtec OdtRimegepant Sulfate17$25,759
XcopriCenobamate14$24,027
Emgality PenGalcanezumab-Gnlm12$8,659
Carbidopa-LevodopaCarbidopa/Levodopa118$5,356
Pyridostigmine Bromide30$4,146
Entacapone20$3,540
Levetiracetam64$3,241
Memantine Hcl61$2,989
Carbamazepine ErCarbamazepine13$2,672
Gabapentin76$2,309
Oxcarbazepine25$2,235
Rivastigmine12$1,813
Divalproex Sodium13$1,535
Lamotrigine63$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acorda Therapeutics, IncInbrija$27,871$80,51813 claims
PfizerNurtec Odt$50$25,75917 claims
SK Life Science, Inc.Xcopri$56$24,02714 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$75$4,14630 claims
Upsher-smith Laboratories LLCTopiramate$14$54858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →